Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 30, 2011. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Purchase Date: June 30, 2011.
- Price Range: Highest price paid was 1,336.5 pence per share; lowest price paid was 1,317 pence per share.
- Treasury Holdings (Settled): 469,174,284 shares (8.37% of total issued share capital).
- Treasury Holdings (Including Unsettled): 470,074,284 shares (9.15% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,135,055,510 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 900,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.15% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the execution of the authorized share buyback program. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total number of shares in issue (5,135,055,510) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.15% including unsettled shares).
- Review the price paid per share (1,317 to 1,336.5 pence) against market prices on June 30, 2011.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.